The Comparative Development of Elevated Resistance to Macrolides in Community-acquired Pneumonia Caused by Streptococcus Pneumoniae

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2014 Oct 23

PMID 25336917

Citations 7

Authors

Josef Yayan

Affiliations

Soon will be listed here.

Abstract

Background: Community-acquired pneumonia (CAP) is an acute inflammation of the lungs, which is often caused by Streptococcus pneumoniae. CAP is the leading cause of death by infectious disease in industrialized countries. Therefore, an immediate and effective antibiotic therapy is of great importance for the nonfatal outcome of the disease. The literature contains increasing data about the development of resistance to antibiotics that are used for the treatment of CAP caused by S. pneumoniae; this article also examines the possible development of resistance to antibiotics in S. pneumoniae in recent years.

Methods: Within the study period of 2004-2014, all hospital charts from patients with CAP caused by S. pneumoniae were collected from the Department of Internal Medicine, Saarland University Medical Center, Homburg/Saar, Germany. The tracheal secretions of S. pneumoniae in CAP patients were obtained by bronchoalveolar lavage; bronchial aspirates were obtained through flexible bronchoscopy and directly from sputum, and blood cultures were examined microbiologically for microorganisms.

Results: From a total of 100 patients with CAP caused by S. pneumoniae, 23 (53.49% [34.78% female], 95% confidence interval, 38.58-68.4) patients with a mean age of 59.78 ± 15.77 years met the inclusion criteria of this investigation. These patients were compared to a total of 20 (46.51% [35% female], 95% confidence interval, 31.6-61.42) patients with a mean age of 58.9 ± 13.36 years with CAP who were infested with S. pneumoniae. In the latter group, the streptococcal antigen was detected in pulmonary aspirations by bronchoscopy or in urine using polymerase chain reaction and a rapid pneumococcal test. Penicillin G and vancomycin had a high rate of sensitivity on the antibiogram for S. pneumoniae, which was obtained by bronchoalveolar lavage, bronchial aspirates through flexible bronchoscopy, and directly from sputum. Even though the rates obtained were without statistical significance, S. pneumoniae had a high resistance to macrolides, namely erythromycin, in patients with CAP. Macrolides, specifically erythromycin (17.39%) and azithromycin (4.35%) and other classes of antibiotics such as tetracycline (4.35%), had a statistically significant resistance to streptococcal pneumonia in patients with CAP (P=0.0009).

Conclusion: Increased resistance was found for macrolides and tetracycline in patients with CAP by S. pneumoniae.

Citing Articles

Azithromycin Exposure Induces Transient Microbial Composition Shifts and Decreases the Airway Microbiota Resilience from Outdoor PM Stress in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled Trial.

Du S, Shang L, Zou X, Deng X, Sun A, Mu S Microbiol Spectr. 2023; 11(3):e0206622.

PMID: 37093053 PMC: 10269807. DOI: 10.1128/spectrum.02066-22.

Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia.

Uddin M, Mohammed T, Metersky M, Anzueto A, Alvarez C, Mortensen E Clin Infect Dis. 2021; 75(1):118-124.

PMID: 34751745 PMC: 9402654. DOI: 10.1093/cid/ciab863.

High proportion of drug-resistant isolates in adult community-acquired pneumonia from Northeast India: A hospital-based study.

Kalita D, Sarma R, Sharma K, Deka S Lung India. 2021; 38(5):460-465.

PMID: 34472525 PMC: 8509170. DOI: 10.4103/lungindia.lungindia_978_20.

and Evaluation of Predicted Pneumococcal UDPG:PP Inhibitors.

Cools F, Triki D, Geerts N, Delputte P, Fourches D, Cos P Front Microbiol. 2020; 11:1596.

PMID: 32760374 PMC: 7373766. DOI: 10.3389/fmicb.2020.01596.

Importance of Mcl-1 for Alveolar Macrophage Apoptosis-associated Bacterial Killing.

Stout-Delgado H Am J Respir Crit Care Med. 2019; 200(1):11-13.

PMID: 30785771 PMC: 6603059. DOI: 10.1164/rccm.201901-0159ED.

References

Kang C, Song J, Kim S, Chung D, Peck K, Thamlikitkul V . Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection. 2012; 41(1):151-7. DOI: 10.1007/s15010-012-0299-5. View

. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001; 56 Suppl 4:IV1-64. PMC: 1765992. DOI: 10.1136/thorax.56.suppl_4.iv1. View

Dylewski J, Davidson R . Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis. 2006; 25(1):39-42. DOI: 10.1007/s10096-005-0081-z. View

Imohl M, van der Linden M . [Invasive pneumococcal disease in Germany in the era of pneumococcal conjugate vaccination]. Dtsch Med Wochenschr. 2014; 139(25-26):1346-51. DOI: 10.1055/s-0034-1370126. View

Scott S, Kardos C . Community-acquired, health care-associated, and ventilator-associated pneumonia: three variations of a serious disease. Crit Care Nurs Clin North Am. 2012; 24(3):431-41. DOI: 10.1016/j.ccell.2012.06.003. View

Schito G, Felmingham D . Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents. 2005; 26(6):479-85. DOI: 10.1016/j.ijantimicag.2005.04.022. View

Kleinpell R, Elpern E . Community-acquired pneumonia: updates in assessment and management. Crit Care Nurs Q. 2004; 27(3):231-40. DOI: 10.1097/00002727-200407000-00004. View

Johansson N, Kalin M, Giske C, Hedlund J . Quantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. Diagn Microbiol Infect Dis. 2007; 60(3):255-61. DOI: 10.1016/j.diagmicrobio.2007.10.011. View

Marchese A, Gualco L, Cochetti I, Montanari M, Speciale A, Musumeci S . Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002). Int J Antimicrob Agents. 2005; 26(2):138-45. DOI: 10.1016/j.ijantimicag.2005.04.006. View

10.

Aspa J, Rajas O, Rodriguez de Castro F . Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother. 2008; 9(2):229-41. DOI: 10.1517/14656566.9.2.229. View

11.

Carlavilla A, Lopez-Medrano F, Chaves F, Villena V, Echave-Sustaeta J, Aguado J . [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema]. Enferm Infecc Microbiol Clin. 2005; 23(5):270-3. DOI: 10.1157/13074967. View

12.

Kattan R, Rayyan A, Zheiman I, Idkeidek S, Baraghithi S, Rishmawi N . Serotype distribution and drug resistance in Streptococcus pneumoniae, Palestinian Territories. Emerg Infect Dis. 2011; 17(1):94-6. PMC: 3204635. DOI: 10.3201/eid1701.100886. View

13.

Beekmann S, Heilmann K, Richter S, Garcia-de-Lomas J, Doern G . Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents. 2005; 25(2):148-56. DOI: 10.1016/j.ijantimicag.2004.09.016. View

14.

Metzler K, Drlica K, Blondeau J . Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2012; 68(3):631-5. PMC: 3566671. DOI: 10.1093/jac/dks461. View

15.

Reinert R, Reinert S, van der Linden M, Cil M, Al-Lahham A, Appelbaum P . Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother. 2005; 49(7):2903-13. PMC: 1168634. DOI: 10.1128/AAC.49.7.2903-2913.2005. View

16.

Deva A, Prasad S, Madappa B, Junjegowda K, Bachu R . Pneumococcal infections at a rural tertiary care hospital: a seven year study on isolation rate, clinical spectrum and antibiogram. J Clin Diagn Res. 2014; 8(2):50-2. PMC: 3972596. DOI: 10.7860/JCDR/2014/7243.4005. View

17.

Hofmann J, Cetron M, Farley M, Baughman W, Facklam R, Elliott J . The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995; 333(8):481-6. DOI: 10.1056/NEJM199508243330803. View

18.

Rzeszutek M, Wierzbowski A, Hoban D, Conly J, Bishai W, Zhanel G . A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents. 2004; 24(2):95-104. DOI: 10.1016/j.ijantimicag.2004.03.008. View